Manufacturer record
Himalaya Meditek Pvt.Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
24 batches manufactured by Himalaya Meditek Pvt.Ltd (Uttarakhand) were declared Not of Standard Quality between February 2019 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
24 records linked to Himalaya Meditek Pvt.Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
24Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
24
NSQ batches since 2019
20
Products affected
Dissolution
Most common failure
Jul 2026
Latest alert
Flagged batches per year
2019 · 22020 · 22021 · 22022 · 12024 · 82025 · 42026 · 5
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Betamethasone Sodium Phosphate Injection I.P. | HL11006MMfg 2025-12 · Exp 2027-11 | The sample does not conforms to the IP with respect to Description, Particulate Matter and Assay.Assay | DTL JaipurState lab | Jul 2026 |
| Hyoscine Butylbromide Injection IP | HLI591HMfg 2025-08 · Exp 2028-07 | The sample does not conform to claim as per IP 2022 in respect to the Test of Particulate matter.Particulate matter | RDTL, ChandigarhCDSCO lab | Apr 2026 |
| Risperidone Tablets IP 4mg | HTN172GMfg 2025-07 · Exp 2027-06 | The sample fails the test 'Dissolution' as per IPDissolution | DTL ThiruvananthapuramState lab | Mar 2026 |
| Omeprazole Capsules IP 20mg | HCN460GMfg 2024-07 · Exp 2026-06 | Dissolution.Dissolution | DTL, Chennai-06State lab | Feb 2026 |
| Atorvastatin Calcium Tablets IP 10mg | HTN792GMfg 2024-07 · Exp 2026-06 | DissolutionDissolution | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Ranitidine Injection IP-2ML | HLI352CMfg 2024-03 · Exp 2026-02 | Sample does not conform to requirement for AssayAssay | King Institute of Preventive Medicine & Research, Guindy, Chennai-32State lab | May 2025 |
| Gentamicin Injection I.P-2ml | HLI624FMfg 2024-06 · Exp 2025-05 | Sample does not conform to the requirement for pHpH | King Institute of Preventive Medicine & Research, Guindy, Chennai-32State lab | May 2025 |
| Omeprazole Capsules IP 20mg | HCN423FMfg 2024-06 · Exp 2026-05 | Sample does not conform to IP specification with respect to Uniformity of weightUniformity of weight/content | DTL MaduraiState lab | Apr 2025 |
| Cefixime Tablets IP 400 mg | HTB404GMfg 2024-07 · Exp 2026-06 | Sample does not conform to IP Specification for Cefixime Tablets with respect to the content of Anhydrous Cefixime in Cefixime Trihydrate.Other | DTL MaduraiState lab | Apr 2025 |
| Metoclopramide HCL Injection I.P-2ml | HLI405DMfg 2024-04 · Exp 2026-03 | sample does not conform to the requirement for Assay of MetoclopramideAssay | King Institute ChennaiState lab | Dec 2024 |
| Ciprofloxacin Hydrochloride Tablets IP 500mg | HTN1126LMfg 2023-11 · Exp 2025-10 | Sample does not conform to IP specification for ciprofloxacin tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Dec 2024 |
| Atorvastatin Calcium Tablets IP 10mg | HTN414DMfg 2024-04 · Exp 2026-03 | Sample does not conform to IP Specification for Atorvastatin Calcium Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Dec 2024 |
| Atorvastatin Calcium Tablets IP 10mg | HTN405DMfg 2024-04 · Exp 2026-03 | Sample does not conform to IP Specification for Atorvastatin Calcium Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Dec 2024 |
| Atorvastatin Calcium Tablets IP 10mg | HTN906JMfg 2023-09 · Exp 2025-08 | Sample does not conform to IP Specification for Atorvastatin Calcium Tablets with respect to DissolutionDissolution | DTL ChennaiState lab | Nov 2024 |
| Panlib -D [Pantoprazole and Domeperidone Tablets] | HTN253DMfg 2024-04 · Exp 2026-03 | It fails the test ?Disintegration? as per IP and the contents of active ingredients of Pantoprazole and Domeperidone are not with in the limits of ?Schedule V? of Drugs and Cosmetics Act & Rules thereunder as specified in the Laboratory ProtocolDisintegration | DTL ThiruvananthapuramState lab | Oct 2024 |
| Wintel 40 Tablets | HTN257DMfg 2024-04 · Exp 2026-03 | It fails the test ?Dissolution? as per IPDissolution | DTL ThiruvananthapuramState lab | Sep 2024 |
| Panlib 40 Tablets | HTN 102AMfg 2024-01 · Exp 2025-12 | It fails the test Dissolution? and ?Assay? as per IPAssay | DTL ThiruvananthapuramState lab | Sep 2024 |
| CLARIFORD-500 (Clarithromycin Tablets IP 500 mg) | HTN303CMfg 2020-03 · Exp 2023-02 | Dissolution and AssayAssay | CDTL MumbaiCDSCO lab | Oct 2022 |
| Zolam 0.25 (Alprazolam Tablets I.P. 0.25 mg) | HLI282BMfg 2020-02 · Exp 2022-01 | DissolutionDissolution | CDL KolkataCDSCO lab | Sep 2021 |
| Hydrocortisone Sodium Succinate Injection I.P. | HDI121AMfg 2020-01 · Exp 2021-12 | Clarity of Solution, Particulate matter, Assay of HydrocortisoneAssay | CDL KolkataCDSCO lab | Aug 2021 |
| Cipjohn 500 (Ciprofloxacin Tablets I.P. 500 mg) | HTN813DMfg 2018-04 · Exp 2021-03 | DissolutionDissolution | CDL KolkataCDSCO lab | May 2020 |
| Metoclopramide Inj. USP 10MG/2ML | HLI933AMfg 2019-01 · Exp 2020-12 | Organic impurities and AssayAssay | RDTL ChandigarhCDSCO lab | Apr 2020 |
| Ciprofloxacin Tablets I.P. 500mg. (Cipjohn- 500) | HTN813DMfg 2018-04 · Exp 2021-03 | DissolutionDissolution | RDTL GuwahatiState lab | Dec 2019 |
| Amoxycillin Capsules IP (Amoxytor-250) | HCB709LMfg 2017-11 · Exp 2020-10 | AssayAssay | Drugs Control Department, Arunachal PradeshCDSCO lab | Feb 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.